ACCESS & equity

One of InGeNA's four strategic pillars is Access and Equity. This pillar is about advocating for patient equity and access to personalised healthcare. Currently, many of the benefits of genomics is not equitably available to patients throughout Australia. In 2022, InGeNA released a white paper under this strategic pillar 'Realising the full potential of genomics to personalise healthcare: Future directions for health technology assessment in Australia.'

About the report:

Realising the full potential of genomics to personalise healthcare

Future directions for health technology assessment in Australia provides a unified industry viewpoint on how the reform of the HTA system could substantially improve and enhance access to genomic technology for health consumers.

InGeNA's view is there would be more equitable access to genomic testing if health technology assessment (HTA) processes were improved.

Genomics is complex and evolving rapidly. Therefore, successful integration into clinical practice will require effective collaboration across the genomics value chain, including Government, pathologists, healthcare professionals, consumers and suppliers of genomic technologies.

This whitepaper was produced by HTANALYSTS, with broad stakeholder input to identify current HTA challenges and potential solutions for genomic technologies such as large panel tests.

The whitepaper outlines how the HTA review could address many challenges such as the length and efficiency of the Medical Services Advisory Committee (MSAC) HTA process, and improve transparency around evidentiary requirements, value definition and transparency.  It says the reform process could also address larger issues such as funding models and broader legislation.

Realising the full potential of genomics to personalise healthcare

Future directions for health technology assessment in Australia

 

Realising the full potential of genomics to personalise healthcare is a whitepaper by HTANALYSTS published by the Industry Genomics Network Alliance (InGeNA). If, for any reason, you have trouble downloading the report, please email us for a direct link.

    InGeNA does not share your information with any third party. Collected information is only used to communicate with you on information pertinent to this report as well as broader InGeNA updates.

    WEBINAR

    InGeNA report launch webinar

    Future directions for health technology assessment in Australia

    Wednesday 15 June 2022 | 12:00pm – 12:45pm AEDT 

    Realising the full potential of genomics to personalise healthcare: Future directions for health technology assessment in Australia was prepared by HTANALYSTS and contains recommendations for action for industry, consumers and policy makers.

    Watch this webinar where we hear key outcomes from the paper, as well as a patient perspective and potential next steps for InGeNA and the broader healthcare community.